Dyax Corp. (NASDAQ: DYAX) the manufacturer of KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older, has announced the launch of its HAE diagnostic testing refund program. The program is designed to help eligible patients cover the out-of-pocket costs associated with HAE diagnostic tests. Patients who currently have a cost share (copay, coinsurance or deductible) or who do not have health insurance coverage for HAE diagnostic testing can now get refunded for these expenses by enrolling in this Dyax program.
There are several programs currently available to financially assist patients already diagnosed with HAE. This program, the first of its kind in HAE, will lower financial hurdles for eligible patients seeking HAE diagnostic testing.
“Healthcare should not be limited by affordability,” said Gustav Christensen, President and Chief Executive Officer of Dyax. “As part of our ongoing dialogue with patients and physicians, we continue to develop programs to meet their needs and bring awareness to this rare and, oftentimes, misdiagnosed disease.”
"The HAEA appreciates Dyax’s continuing efforts to encourage early HAE patient diagnosis and management”, said Janet Long, Executive Vice President, US Hereditary Angioedema Association.Patients can enroll in the program by calling 855-HAE Hope (855-423-4673) or by visiting http://www.haehope.com/haetesting. The HAE diagnostic testing refund program is just part of a suite of services that Dyax provides to HAE patients. To learn more about other Dyax programs, please contact 855-423-4673 or visit www.dyax.com. About HAE Hereditary angioedema (HAE) is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect 1 in 10,000 to 1 in 50,000 individuals. Learn more at www.HAEHope.com. About KALBITOR® (ecallantide) KALBITOR is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. KALBITOR, which was discovered and developed by Dyax, is the first subcutaneous treatment available in the U.S. for treating acute HAE attacks.